Vericel Q2 revenue up 22% to $77.5M, raises FY guidance, authorizes $200M buyback

Vericel Corp

Q2 total revenue $77.5M (+22% YoY); MACI $65.5M (+23%); Burn Care $12.0M (+22%).
Net income $2.2M ($0.04 diluted EPS) vs net loss $0.6M in Q2 2025; adjusted EBITDA margin 19%.
FY 2026 revenue guidance raised to $330-340M (from $326-336M); MACI to $284-290M; Burn Care to $46-50M.
Board authorized $200M share repurchase program; company has $227M cash and no debt.
Free cash flow $14.3M in Q2; record MACI biopsies and implants; UK MHRA submission for MACI.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.